In pharma and biotech, digital systems rarely stay the same after they go live. Workflows change, users increase, integrations are added, suppliers release updates, and the system becomes part of a larger operational environment. The real challenge is that oversight does not always evolve at the same pace. A system may still be validated, documented,
SaaS and cloud validation is different because the regulated company no longer controls the full technical stack, but it still owns intended use, oversight, data integrity, access, and compliance. That is where many teams misunderstand the real validation challenge. When a system is vendor-hosted, the validation work does not go away. It shifts. Instead of
For a growing biotech company, implementing the first major digital system is an important milestone. Paper records, spreadsheets, shared drives, and disconnected tools that worked during early growth may no longer support increasing operational complexity, regulatory expectations, or future scale. The natural response is often to start evaluating software. But selecting an eQMS, LIMS, LMS,
How Assurea validated a U.S. deployment of Veeva Vault Quality and established a reusable validation framework for future global site rollouts. Project Overview When a global Contract Development and Manufacturing Organization (CDMO) selected Veeva Vault Quality to standardize its quality management processes, the first deployment was planned for a U.S. manufacturing site located on the
Many life sciences organizations commonly ask this question when implementing a SaaS platform: “If the vendor already validated the system, what do we still need to do?” The answer is straightforward. The vendor is responsible for the platform it develops, operates, and maintains. The regulated company remains responsible for how that platform is configured, governed,
In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end
The FDA has finalized its Computer Software Assurance for Production and Quality System Software guidance — a long-awaited update that signals the end of “business as usual” for software validation in regulated industries. For decades, Computerized System Validation (CSV) has been the framework life sciences companies relied on. While it provided structure, CSV often created
Whether you’re running a biologics manufacturing plant, managing clinical trial data, or operating a quality management system, your computerized systems play a critical role in ensuring product quality and patient safety. But systems age, users change, processes evolve—and what worked flawlessly two years ago might be a compliance risk today. That’s where periodic reviews come
As biotech companies scale from clinical to commercial manufacturing, expansion of GMP facilities brings both exciting growth opportunities and complex regulatory challenges. One area that demands foresight is Computer System Validation (CSV) — the process of ensuring that software systems used in GMP environments are functioning as intended and in compliance with regulations such as
Setting up a GMP-compliant manufacturing site is one of the most critical steps for a biotech company transitioning into clinical or commercial production. In today’s digital landscape, implementing robust Computer System Validation (CSV) practices from the outset is essential—not only to meet regulatory expectations but to ensure seamless, reliable, and compliant operations across your production